Advanced searches left 3/3

Simvastatin - Crossref

Summarized by Plex Scholar
Last Updated: 09 September 2022

* If you want to update the article please login/register

Evidence-based data on Simvastatin: A 15-year experience

For every 1 % decrease in low-density lipoprotein one, a randomized controlled trials examining statins have shown that a 0. 1 percent decrease in cardiovascular risk can result in a 0. 8 percent decline in cardiovascular risk. simvastatin has been extensively tested in clinical trials with hard end points for the past 15 years. These studies revealed that Simvastatin 20-40 mg/day treatment may not reduce cardiovascular risk by 24-35 percent, coronary disease reduction by 42 percent, risk of stroke by 27 percent, and total mortality by 13-30 percent. Simvastatin was also well studied in regression studies, and regression experiments were also conducted. According to the majority of high-risk patients, optimal LDL-C goals can be met with ezetemibe 10 mg/sim vastatin 20 mg/sim vastatin 20 mg/kg/day, the majority of high-risk patients can meet target LDL-C targets. According to a DYSIS report, simvastatin is the most reliable and widely used statin in the world.

Source link: https://doi.org/10.18705/1607-419x-2010-16-3-238-249


Effect of treatment with simvastatin and cyclosporine on neurotransmitter concentrations in cerebrospinal fluid after subarachnoid hemorrhage in dogs

Objective - U2014 To determine the effects of cyclosporine and simvastatin in dog CSF of experimentally induced subarachnoid hemorrhage, test glucose, aspartate, u03b3-aminobutyric acid, and glycine in CSF of dogs with experimentally induced subarachnoid hemorrhage. Samples of CSF were collected before the first blood transfusion and on days 3, 7, and 10. Result u2014. GABA and glutamate concentrations reached their high on day 3 in control dogs, but there was a significant rise in GABA and glutamate levels on day 3. On day 3, simvastatin alone or simvastatin in combination with cyclosporine was significantly lower, and glycine concentrations were significantly higher, with glycine concentrations elevated, relative to control group concentrations. At any time point, no significant differences in GABA and aspartate levels were found among treatment groups. Conclusions and Clinical Relevance u2014Glutamate concentrations in the CSF of dogs with SAH were elevated.

Source link: https://doi.org/10.2460/ajvr.74.8.1111


Simvastatin Nanoparticles Loaded Polymeric Film as a Potential Strategy for Diabetic Wound Healing: In Vitro and In Vivo Evaluation

Introduction: The pleiotropic effects of statins have been recently investigated for wound healing by angiogenesis and lymphogenesis, which may be of utmost importance in diabetic wounds. Aim: The purpose of this study is to produce nanofilm embedded with simvastatin-loaded chitosan nanoparticles, as well as investigating the effect of SIM in diabetic wound healing. The results revealed the importance of nanofilms filled with SIM-NPs in diabetic wound healing at the wound site, as well as angiogenesis stimulation. Conclusion: CS-SIM-NPs coated polymeric nanofilms may be an emerging diabetic wound healing agent in the field of nanomedicines.

Source link: https://doi.org/10.2174/1567201818666210720150929


Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial

In patients with moderate to severe depression, we wanted to investigate the antidepressant effects of simvastatin as an adjuvant therapy. 48 patients were randomly assigned simvastatin or placebo as an adjunct to fluoxetine for six weeks in this double-blind placebo-controlled clinical trial. Patients were rated with the Hamilton Depression Rating Scale at baseline and weeks 2, 4, and 6. By the time of the trial, Simvastatin-treated patients had significant decreases in HDRS scores compared to the placebo group.

Source link: https://doi.org/10.1177/0269881115578160


Efficiency of atorvastatin and simvastatin in improving cardiac function during the different degrees of hyperhomocysteinemia

The purpose of this study was to determine the effects of atorvastatin and simvastatin on myocardial contractility in rats with different degrees of hyperhomocysteinemia. A research was carried out on adult male Wistar albino rats in which HHcy was caused by diet manipulation. Animals were exposed to pharmacology therapy with atorvastatin in a dose of 3 mg/kg/day, i. p. In states of physiological condition, mild HHcy, and moderate HHcy, the maximum rate of left ventricular growth, minimum rate of left ventricular growth, systolic left ventricular formation, diastolic left ventricular growth, heart rate, and coronary flow were measured. Compared to simvastatin, atorvastatin treatment improved myocyte contractility, notably reduced dp/dt min, and heart rate, leading to greater changes in systolic left ventricular formation.

Source link: https://doi.org/10.1139/cjpp-2018-0102


Simvastatin affects EMT and stemness phenotype of triple negative breast cancer cells

Abstract The three negative breast cancer syndromes are characterized by rapid growth and dissemination. Methods & Results The effect of simvastatin on the cellular viability of the Hs578T TNBC cell line's tough characteristics was investigated, with doses corresponding to 85%, 70%, and 50% of cellular viability. Our results indicate that simvastatin therapy near to the IC 50 level could attenuate the cell's aggressive characteristics. Simvastatin, on the other hand, had a completely different effect at concentrations below IC 50 because it stimulated cell migration and increased the expression of stem cell and EMT markers. Simvastatin also seems to have a suppressive effect on TNBC-specific miRNA expression in a dose-independent manner. Concerns can arise about the tumor drug exposure in patients, particularly for tumor cells, where drug bioavailability could be poor, as the pharmacological response may be different from the expected.

Source link: https://doi.org/10.21203/rs.3.rs-1886748/v1


Preparing simvastatin nanoparticles by a combination of pH-sensitive and timed-release approaches for the potential treatment of ulcerative colitis

In this research, an emulsion solvent evaporation process was used to produce Eudragit RL nanoparticles coated with simvastatin for the treatment of ulcerative colitis. Using the Box-Behnken method, the effects of various formulation variables on the properties of NPs were investigated. Colitis was triggered by 3% of acetic acid in rats, which were NPs of SIM, mesalazine, blank NPs, and normal saline for five days. The optimized SIM-ERL NPs had the particle size of 182. 48 mm, the polydispersity index of 0. 29 nm, and the release yield percentage of 35. 37 percent. With EFS30D, Coating the optimized NPs resulted in an increase in particle size and a decrease in the zeta potential of NPs.

Source link: https://doi.org/10.1177/08853282221122907


Simvastatin Suppresses Interleukin Iβ Release in Human Peripheral Blood Mononuclear Cells Stimulated With Cholesterol Crystals

Here, we investigated the effects of simvastatin therapy on expression levels of interleukin 1u03b2 in both patient with hyperlipidemia and healthy human peripheral blood mononuclear cells using cholesterol crystals, a cardiovascular pathogenic stimulus for inflammation of the NOD-like receptor pyrin domain containing protein 3 inflammasome. Specifically, isolated PBMCs from patients with hyperlipidemia at baseline and simvastatin daily were incubated with lipoaccharide for 3 hours to stimulate proIL-I-u03b2 expression in vivo and simvastatin-induced cellular proliferation for 18 hours, triggering inflammatory maturation/activation of IL-1u03b2 in vivo therapy, with simvastatin in vivo for 8 weeks as a resulte cholade tu03b2 PBMCs from patients with sim2 defasymptoma graftu03b2 u03b2 production/u03b2u03b2u03b2 release of u03b2 a u03b2 release/activation/u03b2 IL-1u03b2 u03b2 chema3u03b2 inflammatory b2 phosphoru03b2 inflammatory tel1u03b2u03b2u03 As explained above, peripheral blood mononuclear cells were also isolated from healthy donors and stimulated in vitro with simvastatin before stimulation with LPS and CC. Enzy-linked immunosorbent assay and western blot demonstrated the effects of simvastatin treatment on levels of IL-1u03b2 expression.

Source link: https://doi.org/10.1177/1074248418776261


FORMULATION AND EVALUATION OF SIMVASTATIN LOADED MICROEMULSION BASED GEL: IN VITRO CHARACTERIZATION

Simvastatin is a BCS class II drug that promotes wound healing by raising the production of vascular endothelial growth factor. Both hydrophobic and hydrophilic agents can be stabilized by a combination of surfactant and cosurfactant that improve skin permeability for both hydrophobic and hydrophilic drugs. The optimized ME gel had an average globule size of 151 nm and had a homogeneous consistency, demonstrated good spreadability, and in vitro drug release. According to the present study, simvastatin-loaded microemulsion gel could be a promising tool for topical drug delivery of diabetic wound healing.

Source link: https://doi.org/10.7897/2230-8407.1207149


SIMVASTATIN-LOADED NANOCAPSULES REDUCE TNF-Α EXPRESSION IN RAT PERITONEUM AFTER INFUSION OF PERITONEAL DIALYSIS SOLUTION

Obteinment and characterization of simvastatin nanocapsules are both essential and investigating their involvement in an experimental model of peritoneal fibrosis caused in a rat by the infusion of peritoneal dialysis solution. By photon correlation spectroscopy, the average particle size and polydispersity index were determined. To determine the drug encapsulation effectiveness, the drug encapsulation rate was used in ultra-high performance liquid chromatography with photodiode array detection was used. In total, 48 male Wistar rats were divided into four groups: Sham, PD group, SV group, and a Simvastatin-loaded nanocapsules group were divided into four groups: Sham, PD group, SV group, and a Simvastatin-loaded nanocapsules group were divided into four groups. Results: NC-SV also reported acceptable particle parameters with a mean particle diameter of 332 nm and an encapsulation rate of 99. 87 percent. u00b10. 46%. The expression of tumor necrosis factor-alpha in the NC-SV group was highly variable. Also at a low SV dose in a chronic PD model, this nanoformulation remarkable reduced TNF-u03b1 tissue expression.

Source link: https://doi.org/10.22159/ajpcr.2021.v14i7.41562

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions